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Improving Human Papillomavirus Vaccination in the United 
States: Executive Summary
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This special issue of Academic Pediatrics highlights promising research as well as continued 
challenges with improving human papillomavirus (HPV) vaccination coverage among 
adolescents in the United States. As Markowitz and colleagues review, in the first 10 years 
of the US HPV vaccination program, there have been advances with available vaccines, 
expansion of vaccine recommendations, and early success with reducing prevalence of HPV 
vaccine types among adolescents and young adults.1 However, despite the availability of a 
safe and effective vaccine, HPV vaccine uptake has been lower than expected. The 7 
commentaries and 11 original articles, from noted experts included in this supplement 
highlight challenges, successes, and lessons about HPV vaccination delivery in the United 
States. These articles are organized according to population: parent, provider, and system.
Parents and adolescents themselves are the ultimate decision-makers regarding HPV 
vaccination. In the parent perspectives section, a commentary by Ernst and Shelby2 touches 
on the positive and negative roles social media have played regarding HPV vaccination, 
encouraging the sharing of HPV cancer stories to highlight the importance of vaccination. 
This theme continues with a personal story from an HPV cancer survivor in the commentary 
by Perkins and Felder.3 Dempsey and O’Leary4 conduct a review of the influence that 
provider communication techniques have on parental attitudes regarding HPV vaccine, as 
well as how those techniques affect vaccination uptake, and describe the evidence that 
strong, brief, unambiguous provider recommendations are effective. Chhabra et al5 use a 
health literacy framework (readability, suitability, and comprehensiveness of content) to 
evaluate 38 HPV counseling materials; although many materials scored low for readability, a 
qualitative review of 4 products by parents showed that the documents were influential in 
convincing them to vaccinate. The final article in this section, by Kornides et al,6 
summarizes the results of a survey of parents who initially refused the HPV vaccine for their 
child—45% reported accepting the vaccine on subsequent visits with their health care 
provider, showing the importance of repeatedly discussing HPV vaccination with patients 
even if parents initially decline the vaccine.
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Health care practitioners can help raise HPV vaccination rates by focusing on optimal 
communication techniques as well as implementing one or more practice-based changes. In 
the provider perspective section, Stratbucker et al7 present a model for educating residents 
that includes experiential and longitudinal quality improvement (QI) activities focused on 
improving vaccination rates and reducing missed opportunities. This involves a 
multidisciplinary office-based team and gives the resident an opportunity to learn about 
office systems, communication, and QI methodology. Rand et al8 put this model into 
practice with a 9-month learning collaborative QI intervention in 38 community practices 
and 14 pediatric continuity clinics resulting in an increase in HPV vaccination and a 
decrease in missed vaccination opportunities. Rosen and Kahn9 synthesize the literature in a 
qualitative review of the empirical research examining health care clinicians’ perceptions 
and professional practices concerning HPV vaccination; although providers are supportive of 
HPV vaccination in general, discrepancies were identified between stated intentions and 
recommendation practices. Finally, Zimet et al10 present an intervention study in which the 
comparative effectiveness of 2 interventions were evaluated: simple prompts delivered via an 
electronic clinical decision support system versus elaborate prompts that include specific 
phrases and strong provider recommendation language, versus standard of care control; this 
study was conducted with 29 pediatric health care providers in 5 pediatric clinics. Zimet et al 
report that vaccine initiation was significantly higher in the elaborate prompt arm compared 
with the control arm but the same in the simple prompt versus control arms.
Interventions can occur beyond the individual doctor–patient encounter, or the individual 
medical practice—in fact, system-based interventions are also needed. In the final section, 
systems perspectives, Rand and Goldstein11 provide an overview of health care utilization 
among individuals ages 9 to 21 years to highlight how often eligible children and 
adolescents “touch” the health care system and therefore have opportunities for vaccination. 
Only 35% made a preventive health care visit during the past 12 months with visits 
decreasing after age 16 years, highlighting the importance of taking advantage of every 
health care encounter and providing HPV vaccine at the recommended age of 11 to 12 years. 
Two intervention studies targeting large health systems included in this section show mixed 
results, highlighting the continued challenge of improving HPV vaccination. Fisher-Borne et 
al12 describe early results from a 3-arm QI pilot study conducted in 30 federally qualified 
health center systems, representing 130 clinic sites. This study showed a 14.6 percentage 
point increase in HPV vaccine series initiation among 11- to 12-year-old patients during the 
first year, however, no significant increases were observed for vaccination with the second 
dose or series completion. An assessment and feedback intervention study by Irving and 
colleagues13 conducted in 9 Oregon-based outpatient clinics in an integrated health care 
delivery system showed no effect on HPV vaccination coverage, demonstrating the 
challenges with improving coverage in a system that had already been implementing most 
recommended strategies. Beyond the health care setting, Choi et al14 summarize a multi-
intervention approach implemented in the City of Chicago from September 2013 through 
December 2015 that focused on creating a stakeholder initiative, provider and public 
education, and system interventions including provider peer-to-peer immunization practices 
assessment and feedback visits. Although this was a multipronged community intervention 
and not a randomized trial and vaccine coverage cannot be attributed solely to the 
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intervention, HPV vaccination rates in targeted Chicago areas were higher than before the 
intervention. Last, although school-located vaccination has been a successful model in 
increasing HPV vaccination coverage in other countries, Kempe et al15 review the published 
literature and outline the many challenges as well as opportunities with implementing 
school-located vaccination in the United States.
A multidisciplinary approach, with many partners, is needed to improve HPV vaccination 
delivery. Saslow et al16 describe the efforts of the National HPV Roundtable to bring 
together organizations with a shared goal of improving vaccine uptake and reducing cancers 
caused by HPV. Additionally, Reiter et al17 outline research gaps that, if addressed, can help 
guide activities as we begin the second decade of HPV vaccination in the US. Indeed, as 
explained in the commentary by Schuchat, continued efforts are needed from many 
disciplines to help tackle this important public health issue and end “HPV vaccine 
exceptionalism” with a renewed effort to normalize HPV vaccination into standard 
recommended health care.18
As shown in this supplement, improving HPV vaccination coverage in the United States has 
many challenges but some approaches are showing promise. By working together and by 
pushing ourselves to work “smarter” and incorporate the latest evidence and expertise about 
HPV vaccination delivery, we can hasten the process of ridding the nation of HPV disease.
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